Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study

Area of Science:

• Neurology
• Clinical Trials
• Biostatistics

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease.
• Riluzole is an approved medication for ALS, but its stage-specific effects require further elucidation.
• Understanding treatment efficacy across different disease stages is crucial for patient management and research.

Purpose of the Study:

• To estimate the stage-specific effect of riluzole on the risk of progression in Amyotrophic Lateral Sclerosis (ALS).
• To analyze treatment effects using distinct staging systems (King's and FT9) within the PRO-ACT dataset.
• To apply Markov multistate models for estimating hazard ratios associated with riluzole treatment.

Main Methods:

• Utilized the PRO-ACT dataset comprising 1903 ALS patients, with 1587 receiving riluzole.
• Employed two staging methods (King's and FT9) to categorize disease progression.
• Applied unadjusted and adjusted Markov multistate models to estimate hazard ratios for stage transitions.

Main Results:

• Riluzole treatment was associated with a non-significant trend towards longer survival (median 22.9 vs. 18.3 months).
• Adjusted models revealed riluzole significantly reduced progression risk in specific transitions: King's stages 1->2, 2->3, 4->death; FT9 stages 1->2, 3->4, 4->death.
• For bulbar-onset ALS, riluzole's benefit was observed in earlier King's stages.

Conclusions:

• Riluzole demonstrates a predominantly beneficial effect on slowing ALS progression, particularly in later disease stages.
• The study's analytical framework is valuable for identifying stage-specific treatment effects in ALS.
• Findings support refined health economic analyses and clinical decision-making regarding riluzole use in ALS.